NCT05405621 - Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions

Locally Advanced/Metastatic Solid Tumours

Interventions

DRUG

BAT8009 for Injection

BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou